Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat.
Open Access
- 24 November 1998
- journal article
- other
- Published by Wolters Kluwer Health in Circulation
- Vol. 98 (21) , 2323-2330
- https://doi.org/10.1161/01.cir.98.21.2323
Abstract
Background —Endothelin A (ET A ) receptor antagonists have been shown to improve ventricular remodeling and survival in rats when started 10 days after infarction. Whether starting them earlier would have a more or less beneficial effect is uncertain. Methods and Results —Rats surviving an acute myocardial infarction (MI) for 24 hours (n=403) were assigned to saline or the ET A receptor antagonist LU 127043 or its active enantiomer LU 135252 for 4 weeks. Chronic LU treatment had no effect on survival, with 46% of LU rats and 47% of saline-treated rats with large MI surviving to the end of the study. LU treatment led to scar thinning, further left ventricular (LV) dilatation, an increase in LV end-diastolic pressure, and an increase in wet lung weight ( P P Conclusions —The early use of the ET A receptor antagonists LU 127043 or its active enantiomer LU 135252 after infarction in the rat leads to impaired scar healing and LV dilatation and dysfunction. This is accompanied by a decrease in RV systolic and right atrial pressures and a decrease in pulmonary but not cardiac ET-1 levels. It would thus appear that the early use of ET A receptor antagonists after infarction may be detrimental.Keywords
This publication has 6 references indexed in Scilit:
- Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in ratsJournal of the American College of Cardiology, 1996
- INCREASED ENDOTHELIN EXPRESSION IN A RAT CARDIAC ALLOGRAFT MODEL OF CHRONIC VASCULAR REJECTION1Transplantation, 1996
- Discovery and Optimization of a Novel Class of Orally Active Nonpeptidic Endothelin-A Receptor AntagonistsJournal of Medicinal Chemistry, 1996
- Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failureThe Lancet, 1995
- Markedly different effects on ventricular remodelling result in a decrease in inducibility of ventricular arrhythmiasJournal of the American College of Cardiology, 1994
- A novel potent vasoconstrictor peptide produced by vascular endothelial cellsNature, 1988